Alpha-lipoic acid inhibits fractalkine expression and prevents neointimal hyperplasia after balloon injury in rat carotid artery

Atherosclerosis

Volumn 189, Issue 1, 2006, Pages 106-114

  Lee, Kyeong Min ^a   Park, Keun Gyu ^a   Kim, Yong Deuk ^a   Lee, Hyo Jung ^a   Kim, Hyoung Tae ^a   Cho, Won Hyun ^a   Kim, Hye Soon ^a   Han, Seong Wook ^a   Koh, Gou Young ^b   Park, Joong Yeol ^c   Lee, Ki Up ^c   Kim, Jung Guk ^d   Lee, In Kyu ^d  

^a Keimyung University School of Medicine   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

Author keywords

Lipoic acid; Atherosclerosis; Fractalkine; Neointimal hyperplasia; NF B; Vascular smooth muscle cell

Indexed keywords

CYTOKINE; FRACTALKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HYPERPLASIA; INHIBITION KINETICS; MALE; NEOINTIMA HYPERPLASIA; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM;

ANGIOPLASTY, BALLOON; ANIMALS; ANTIOXIDANTS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CAROTID ARTERY DISEASES; CELLS, CULTURED; CHEMOKINE CX3CL1; CHEMOKINES, CX3C; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA; GENE EXPRESSION; HYPERPLASIA; MALE; MEMBRANE PROTEINS; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; THIOCTIC ACID; TUNICA INTIMA;

EID: 33747770115     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.12.003     Document Type: Article

References (29)

1. Liu M.W., Roubin G.S., and King III S.B. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 79 (1989) 1374-1387
2. Toutouzas K., Colombo A., and Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25 (2004) 1679-1687
3. Bonz A.W., Lengenfelder B., Jacobs M., et al. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J 145 (2003) 693-699
4. Braun M., Pietsch P., Zepp A., et al. Regulation of tumor necrosis factor alpha- and interleukin-1-beta-induced induced adhesion molecule expression in human vascular smooth muscle cells by cAMP. Arterioscler Thromb Vasc Biol 17 (1997) 2568-2575
5. Barks J.L., McQuillan J.J., and Iademarco M.F. TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J Immunol 159 (1997) 4532-4538
6. Bustos C., Hernandez-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32 (1998) 2057-2064
7. Bazan J.F., Bacon K.B., Hardiman G., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 85 (1997) 640-644
8. Lesnik P., Haskell C.A., and Charo I.F. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 111 (2003) 333-340
9. Moatti D., Faure S., Fumeron F., et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97 (2001) 1925-1928
10. Combadiere C., Potteaux S., Gao J.L., et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107 (2003) 1009-1016
11. Yokoyama M. Oxidant stress and atherosclerosis. Curr Opin Pharmacol 4 (2004) 110-115
12. Guha M., Bai W., Nadler J.L., and Natarajan R. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 275 (2000) 17728-17739
13. Bourcier T., Sukhova G., and Libby P. The Nuclear Factor kappa-B Signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 272 (1997) 15817-15824
14. Yoshimura S., Morishita R., Hayashi K., et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther 8 (2001) 1635-1642
15. Packer L., Witt E.H., and Tritschler H.J. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 19 (1995) 227-250
16. Kunt T., Forst T., Wilhelm A., et al. Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulatin with advanced glycation end products. Clin Sci 96 (1999) 75-82
17. Zhang W.J., and Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J 15 (2001) 2423-2432
18. Park K.G., Kim M.J., Kim H.S., et al. Prevention and treatment of macroangiopathy: focusing on oxidative stress. Diab Res Clin Pract 66 (2004) S57-S62
19. Ahn S.Y., Cho C.H., Park K.G., et al. Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol 164 (2004) 1663-1672
20. Ahn J.D., Morishita R., Kaneda Y., et al. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ Res 90 (2002) 1325-1332
21. Ahn J.D., Kim C.H., Magae J., et al. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells. Biochem Biophys Res Commun 310 (2003) 1048-1053
22. Ahn J.D., Morishita R., Kaneda Y., et al. Transcription factor decoy for activator protein-1 (AP-1) inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor (PAI-1) gene expression in cultured human vascular smooth muscle cells. Diabetologia 44 (2001) 713-720
23. Chandrasekar B., Mummidi S., Perla R.P., et al. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 373 (2003) 547-558
24. Chen Y.M., Tu C.J., Hung K.Y., et al. Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation. Br J Pharmacol 138 (2003) 950-958
25. Ametov A.S., Barinov A., Dyck P.J., et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diab Care 26 (2003) 770-776
26. Teichert J., Hermann R., Ruus P., and Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol 43 (2003) 1257-1267
27. Morice M.C., Serruys P.W., Sousa J.E., et al., RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
28. Park S.J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348 (2003) 1537-1545
29. Welt F.G., and Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22 (2002) 1769-1776